{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:43:01Z","timestamp":1789706581426,"version":"4.0.1"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis is a chronic inflammatory disease associated with significant long-term cumulative life course impairment. Achieving rapid relief from psoriasis is a crucial aspect of an effective treatment, as it helps patients manage their daily discomfort, including pain, itching, embarrassment and other negative impacts of the disease. Cumulative clinical benefit, measured as the area under the curve (AUC) of Psoriasis Area and Severity Index (PASI) responses and days free of disease, offers a comprehensive assessment of treatment efficacy over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the cumulative clinical benefits of biologic therapies in patients with moderate-to-severe plaque psoriasis in a real-world Italian multicentre setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre retrospective real-life study included patients treated with bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab or ustekinumab at 23 Italian referral centres. Cumulative benefit was assessed by the AUC of PASI 100 (100% improvement from baseline) from week 0 to week 52, and days free of disease (PASI 100). Analyses included subgroup evaluations by biologic-naive status and baseline PASI (\u2264 10 vs. &amp;gt; 10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1017 patients, bimekizumab showed the highest cumulative clinical benefit, with a mean of 203\u2005days free of disease. It was significantly superior to guselkumab (P &amp;lt; 0.05), secukinumab (P &amp;lt; 0.01), ustekinumab (P &amp;lt; 0.01) and tildrakizumab (P &amp;lt; 0.001). The advantage was consistent across subgroups, with 216\u2005days free of disease in biologic-naive and 184 in biologic-experienced patients. No significant differences were found between bimekizumab and ixekizumab, brodalumab or risankizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this multicentre real-life study, bimekizumab showed exploratory evidence of the cumulative clinical benefit of biologics in moderate-to-severe psoriasis. These findings highlight the importance of cumulative endpoints and individualized treatment strategies in daily practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf486","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:04:00Z","timestamp":1761915840000},"page":"418-426","source":"Crossref","is-referenced-by-count":2,"title":["Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience \u2013 IL PSO (Italian Landscape Psoriasis)"],"prefix":"10.1093","volume":"51","author":[{"given":"Diego","family":"Orsini","sequence":"first","affiliation":[{"name":"Clinical Dermatology Unit, San Gallicano Dermatological Institute , IRCCS, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Assorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Giovanni","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8231-2205","authenticated-orcid":false,"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Veronica","family":"Di Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Tano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Travaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"2026022406172906600_llaf486-B1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000350008","article-title":"Cumulative life course impairment: evidence for psoriasis","volume":"44","author":"Mattei","year":"2013","journal-title":"Curr Probl Dermatol"},{"key":"2026022406172906600_llaf486-B2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/09546634.2016.1214667","article-title":"Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis","volume":"28","author":"Armstrong","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"2026022406172906600_llaf486-B3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.wndm.2013.06.001","article-title":"Cumulative life course impairment (CLCI): a new concept to characterize persistent patient burden in chronic wounds","volume":"1","author":"Augustin","year":"2013","journal-title":"Wound Med"},{"key":"2026022406172906600_llaf486-B4","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaad.2019.12.038","article-title":"Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis","volume":"82","author":"Warren","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026022406172906600_llaf486-B5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s13555-022-00690-5","article-title":"Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1\u2005year: a network meta-analysis","volume":"12","author":"Blauvelt","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026022406172906600_llaf486-B6","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s13555-024-01105-3","article-title":"Comparative effectiveness and durability of biologics in clinical practice: month 12 outcomes from the international, observational Psoriasis Study of Health Outcomes (PSoHO)","volume":"14","author":"Pinter","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026022406172906600_llaf486-B7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2026022406172906600_llaf486-B8","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1007\/s13555-024-01229-6","article-title":"Comparison of drug-free remission after the end of phase III trials of three different anti-IL-23 inhibitors in psoriasis","volume":"14","author":"Hsieh","year":"2024","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf486\/65052369\/llaf486.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/3\/418\/65052369\/llaf486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/3\/418\/65052369\/llaf486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:17:34Z","timestamp":1771931854000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/3\/418\/8307694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":8,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,1]]},"published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf486","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,11,1]]}}}